- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03591055
Frailty Assessment and Treatment Strategies in the Elderly at Risk of Functional Decline in the Community
Frailty Assessment and Multimodal Treatment Strategies in the Elderly at Risk of Adverse Results and Functional Decline in the Community
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective: To design and evaluate the implementation and impact of a multimodal intervention focused on elderly patients living in the community in preventing or delaying frailty, functional decline and risk of institutionalization, hospitalization and death.
Design: Study in two phases: a qualitative study to develop the intervention and a randomized clinical trial with parallel arms and control group.
Intervention: Participants in the control group will receive the usual standard care and regular referrals. Patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment (CGA). Then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment, along with medication review, aerobics exercise plan and memory workshops following the model adapted in Phase I.
After 3 and 18 months, measures of functional and cognitive performance, quality of life, frailty, adverse outcomes (institutionalization, hospitalization, death) and health care costs will be collected.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08007
- IDIAP JGol
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Positive screen in the accumulation of deficits electronic frailty index
- Positive screen with Gerontopole screening tool and/or RISC tool
Exclusion Criteria:
- Living in an institution
- Advanced conditions with short life expectancy
- Severe disability
- Severe Dementia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Group
Patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment.
Then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment.
All participants in the intervention group will undergo a medication review and will also perform an aerobics exercise plan in the primary care centre, 60-minute session twice a week on non-consecutive days for 6 weeks (12 sessions of 60 minutes each) and memory workshops (10 sessions).
|
Comprehensive geriatric assessment.
Patient-centered interventions according to the different target areas identified in the geriatric assessment.
Medication review.
Groupal Exercise plan and memory workshops.
|
No Intervention: Control group
Participants in the control group will receive the usual standard care and regular referrals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Short Physical Performance Battery (SPPB) at 3 and 18 months
Time Frame: 0, 3, 18 months
|
The Short Physical Performance Battery (SPPB) is a standardised assessment tool of lower limb function, testing 3 dimensions: standing balance, walking speed, and chair stands.
Each component is scored between 0-4, total score from 0 (poor performance) to 12 (best performance).
|
0, 3, 18 months
|
Change from Baseline in the Quick Mild Cognitive Impairment Screen (Qmci-S) at 3 and 18 months
Time Frame: 0, 3, 18 months
|
The Quick Mild Cognitive Impairment (Qmci) screen is a multi-purpose, short cognitive screening instrument designed to differentiate between normal cognitive function, subjective cognitive disorders, mild cognitive impairment (MCI) and early dementia and to measure change over time.
|
0, 3, 18 months
|
Change from Baseline in Health Related Quality of Life (EuroQol 5D) at 3 and 18 months
Time Frame: 0, 3, 18 months
|
EuroQol 5D EQ-5D is a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal.
|
0, 3, 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Functional Capacity at 3 and 18 months
Time Frame: 0, 3, 18 months
|
Activities of daily living: Barthel Index and Lawton&Brody Index
|
0, 3, 18 months
|
Change from Baseline in the Risk Instrument for Screening in the Community (RISC) at 3 and 18 months
Time Frame: 0, 3, 18 months
|
Risk Instrument for Screening in the Community is a validated short (2-5 min), global subjective assessment of risk created to identify patients' 1-year risk of three outcomes: institutionalization, hospitalization and death.
|
0, 3, 18 months
|
Change from Baseline in Clinical Frailty Scale (CFS) at 3 and 18 months
Time Frame: 0,3 18 months
|
The clinical frailty scale is a 9 points measure of frailty based on clinical judgement.
|
0,3 18 months
|
Change from Baseline in the Gerontopole Frailty Screening Tool (GFST) at 3 and 18 months
Time Frame: 0,3,18 months
|
Gerontopole Frailty Screening Tool is a questionnaire aimed to measure general signs and/or symptoms potentially indicating the presence of an underlying frailty.
These questions largely mirror the criteria that are commonly used to operationalize the frailty status.
|
0,3,18 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Institutionalized during follow-up, at 18 months
Time Frame: 18 months
|
Admission to long-term care {nursing home}
|
18 months
|
Number of Participants Hospitalized during follow-up, at 18 months
Time Frame: 18 months
|
Hospitalization including prolonged admission or readmission
|
18 months
|
Number of Participants who die during follow-up, at 18 months
Time Frame: 18 months
|
Death
|
18 months
|
Health care costs
Time Frame: 18 months
|
Direct health care costs
|
18 months
|
Number of participants that comply with the programme schedules at 3 and 18 months
Time Frame: 3 months and 18 months
|
Compliance with the programme: number of undergone interventions out of total prescribed interventions (including activities, referrals or prescriptions)
|
3 months and 18 months
|
Number of participants (patients, caregivers and professionals) that are satisfied with the programme at 3 and 18 months
Time Frame: 3 months and 18 months
|
Satisfaction with the programme, measured with an ad hoc questionnaire.
|
3 months and 18 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: FRANCISCO Orfila Pernas, Institut Catala de Salut
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI16/01683
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frail Elderly Syndrome
-
DSM Nutritional Products, Inc.CompletedFrail Elderly | Pre-frail ElderlyNetherlands
-
McMaster UniversityAlberta Health services; Saskatchewan Health Authority - Regina Area; Canadian... and other collaboratorsActive, not recruitingFrail Elderly SyndromeCanada
-
Università degli Studi del Piemonte Orientale "Amedeo...Completed
-
University of Massachusetts, WorcesterAnesthesia Patient Safety FoundationCompleted
-
School of Health Sciences GenevaInstitution genevoise de maintien à domicileCompletedFrail Elderly Syndrome
-
University of GlasgowNHS Greater Glasgow and ClydeUnknownFrail Elderly SyndromeUnited Kingdom
-
Castilla-La Mancha Health ServiceColegio Oficial de Terapeutas Ocupacionales de Castilla - La Mancha; Fundación... and other collaboratorsRecruiting
-
Federico II UniversityRecruiting
-
Guang Yang, Prof. Dr.CompletedFrail Elderly SyndromeChina
Clinical Trials on CGA, medication review, exercise and cognitive stimulation
-
Diakonhjemmet HospitalUniversity of Oslo; Diakonhjemmet Hospital Pharmacy; Diakonhjemmet FoundationCompletedDrug-Related Side Effects and Adverse Reactions | Drug Interaction Potentiation | Medication Compliance | Remission | Medicinal Substance; Adverse EffectNorway
-
Universitaire Ziekenhuizen KU LeuvenWithdrawn
-
Monash University MalaysiaRecruitingPain | OsteoarthritisNepal
-
Aarhus University HospitalCompleted
-
Göran PeterssonThe Kamprad Family Foundation for Entrepreneurship, Research & CharityCompletedCoronary Heart DiseaseSweden
-
University of GroningenCompletedPolypharmacy | Cholinergic AntagonistsNetherlands
-
Fundacion Miguel ServetRecruitingCognitive Change | Frailty | Exercise | Fall | Cognition Disorders in Old AgeSpain
-
Hadassah Medical OrganizationUnknown
-
University of BarcelonaMinisterio de Economía y Competitividad, SpainCompleted